Navigation Links
New treatment for rabies advances after successful phase 1 trial in India
Date:9/16/2010

BOSTON, Mass.With the potential to save tens of thousands of lives each year, a new cost-effective rabies therapy developed by MassBiologics at the University of Massachusetts and the Serum Institute of India took an important step forward with positive results from a Phase 1 study. The recently completed study showed that a new monoclonal antibody (RAB-1) resulted in protective antibody levels in the serum of treated subjects equal to the current standard of treatment, which is often not available in the areas of the world hit hardest by rabies.

Details of the study were reported on September 14 at the American Society for Microbiology's 50th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Boston, Massachusetts in a poster presentation titled, "A Human Monoclonal Antibody to Rabies Virus Provides Protective Neutralizing Activity: Results of a Phase 1 Study," by researchers from MassBiologics; the Serum Institute of India in Pune, India; and King Edward Memorial Hospital (KEM) in Mumbai, India.

"We are very encouraged by the results from this trial," said Donna Ambrosino, MD, executive director of MassBiologics and a professor of pediatrics at the Medical School.

Subhash Kapre, PhD, of the Serum Institute of India, agreed saying, "The next step for clinical studies is already in the planning, and we are hopeful that this new therapy will have a major impact on rabies across the globe in the not too distant future."

The World Health Organization estimates that more than 10 million people are exposed to rabid animals each year, resulting in more than 55,000 deaths. Approximately 95 percent of human deaths from rabies occur in Asia and Africa. Untreated, the rabies virus causes an acute encephalitis that is fatal once symptoms appear; however the infection is preventable by prompt treatment following exposure, a procedure known as post-exposure prophylaxis (PEP) that involves adminis
'/>"/>

Contact: Michael Cohen
Michael.Cohen@umassmed.edu
508-868-4778
University of Massachusetts Medical School
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Bion Announces Approval of New U.S. Patent for Phosphorus Removal Process for Livestock Waste Environmental Treatment
2. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
3. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
4. Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11
5. Reliant Technologies Announces Canadian Launch of Fraxel re:pair(R) Laser: A New Class of Treatment Therapy for CO2 Laser Skin Resurfacing
6. With the BEAUTIFUL Results, Procoralan* (ivabradine) is the First Antianginal Treatment Shown to Reduce Myocardial Infarction (Heart Attack) and Revascularisation in Stable Coronary Patients
7. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
8. BioMS Medicals lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
9. Revolutionary New In-Office EVOLVE(R) Laser Prostate Treatment Available Throughout Western Oregon
10. Orange Coast Urology Offers Advanced In-Office Patient EVOLVE(R) Laser Prostate Treatment
11. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... White papers by Clinovo ... eClinical technologies, have been published by leading pharmaceutical publications ... long line of white papers by Clinovo to have ... Leader, Pharmaceutical Online, and OpenHealthNews. , At the request ... CTO Marc Desgrousilliers, 'The Five Essentials of Cloud ...
(Date:7/29/2014)... July 29, 2014 ... (LBS) zur Erfassung biologischer Daten in Verbindung ... und patentiert. Das LBS nimmt gleichzeitig mehrere ... des Patienten und sucht erhöhte biologische Aktivitäten ... Potenzial, die Entdeckung und Entwicklung neuer Medikamente ...
(Date:7/28/2014)... SAN DIEGO , July 28, 2014 ... algae cultivation technologies, today announced the appointment of biotechnology ... member of the board of directors. Levine replaces Cynthia ... effective immediately. She will remain chairman of the company,s ... leadership on Sapphire Energy,s mission to deliver commercial scale ...
(Date:7/28/2014)... 2014 “2014 Deep Research ... is a professional and in-depth research report ... report introduces Lubricant basic information, including Lubricant ... and industry overview. This research covers the ... as well as global industry analysis covering ...
Breaking Biology Technology:Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 2PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 4Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 2Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 3Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 4
... completed phase of the new Children,s,Hospital campus, PITTSBURGH, ... opened its new 10-story, state-of-the-art John G. Rangos,Sr. Research ... new,premier pediatric campus., With more than 300,000 square ... hub of pediatric health research for the region. The ...
... October 29, Rosetta Genomics Ltd. (Nasdaq: ROSG ), ... today its,management will present at Oppenheimer 19th Annual ... Waldorf-Astoria Hotel in New York,City., About MicroRNA, ... small,RNAs that act as master regulators and have ...
... at ImClone Brings Substantial,Oncology Drug Development Expertise, ... ("Senesco" or the "Company") (NYSE Alternext US: SNT),announced ... 55 to its board,of directors. Senesco,s board of ... are independent., (Photo: http://www.newscom.com/cgi-bin/prnh/20081029/NY42202 ), ...
Cached Biology Technology:Opening Dedication of the New John G. Rangos Sr. Research Center at the New Children's Hospital of Pittsburgh of UPMC Campus in Lawrenceville 2Opening Dedication of the New John G. Rangos Sr. Research Center at the New Children's Hospital of Pittsburgh of UPMC Campus in Lawrenceville 3Rosetta Genomics to Present at Oppenheimer's 19th Annual Healthcare Conference 2Rosetta Genomics to Present at Oppenheimer's 19th Annual Healthcare Conference 3Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors 2Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors 3
(Date:7/28/2014)... An international team of researchers led by the University ... rice. , The genetic information will enhance scientists, and ... as well as enable the development of new rice ... environmental stressors to help solve global hunger challenges. , ... Oryza glaberrima ) and evidence for independent domestication," was ...
(Date:7/28/2014)... Reactions among minerals and organic compounds in hydrothermal environments ... they provide energy for the deep biosphere, and may ... little is known about how minerals influence organic reactions. ... have demonstrated how a common mineral acts as a ... need for toxic solvents or expensive reagents. , At ...
(Date:7/28/2014)... mechanism in part of the brain that is key to ... type 1 and type 2 diabetes. The findings are published ... National Academies of Sciences . , "We,ve discovered that ... the hypothalamus known as the ventromedial nucleus sets a ... the blood," said lead author Sabrina Diano, professor in the ...
Breaking Biology News(10 mins):Generating a genome to feed the world: UA-led team sequences African rice 2Generating a genome to feed the world: UA-led team sequences African rice 3Generating a genome to feed the world: UA-led team sequences African rice 4Mineral magic? Common mineral capable of making and breaking bonds 2Mineral magic? Common mineral capable of making and breaking bonds 3Glucose 'control switch' in the brain key to both types of diabetes 2
... are primary producers of ammonia in Houston,s atmosphere, and cars ... according to a new study by researchers at Rice University ... air quality draws minimal oversight from the Environmental Protection Agency ... it means to life in and around the metropolis. ...
... N.Y. DNA and protein sequencing have forever ... of these complex biomolecules has revolutionized drug development, ... evolution and development. But, one major molecule in ... biopolymers. Today, for the first time ...
... A tiny piece of a critical receptor that fuels the ... discovered by University at Buffalo scientists as a promising new ... on the NMDA (N-methyl-D-aspartate) receptor is being published online Oct. ... time that this site has been shown to be useful ...
Cached Biology News:Ammonia gets overdue overview 2Ammonia gets overdue overview 3Uncharted territory: Scientists sequence the first carbohydrate biopolymer 2Uncharted territory: Scientists sequence the first carbohydrate biopolymer 3New drug target for Alzheimer's, stroke is discovered by University at Buffalo scientists 2
Polyclonal antiserum raised against conjugated L-isoleucine. Available as antiserum. Amino Acid Antibodies...
Rabbit polyclonal to FOXJ2 ( Abpromise for all tested applications). entrezGeneID: 55810 SwissProtID: Q9P0K8...
Rabbit polyclonal to Oct2, prediluted ( Abpromise for all tested applications). entrezGeneID: 5452 SwissProtID: P09086...
Macrophage-stimulating protein receptor...
Biology Products: